Radiation countermeasure agents: an update

Bibliography

• Lehnert S. Biomolecular action of ionizing radiation. Series in medical physics and biomedical engineering. Taylor & Francis Group; 2007
   Google Scholar
• Bischoff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Patents 2009;19:643-62
   PubMed Web of Science ®Google Scholar
• Dumont F, Altmeyer A, Bischoff P. Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opin Ther Patents 2009;19:775-99
   PubMed Web of Science ®Google Scholar
• Stone HB, Coleman CN, Anscher MS, Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4:529-36
   PubMed Web of Science ®Google Scholar
• Waselenko JK, MacVittie TJ, Blakely WF, Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004;140:1037-51
   PubMed Web of Science ®Google Scholar
• Ghafoori P, Marks LB, Vujaskovic Z, Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) 2008;22:37-47
   PubMed Web of Science ®Google Scholar
• Moulder JE, Cohen EP. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 2007;17:141-8
   PubMed Web of Science ®Google Scholar
• Maisin JR. Bacq and Alexander Award lecture–chemical radioprotection: past, present, and future prospects. Int J Radiat Biol 1998;73:443-50
   PubMed Web of Science ®Google Scholar
• Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov Today 2007;12:794-805
   PubMed Web of Science ®Google Scholar
• Brizel DM. Pharmacologic approaches to radiation protection. J Clin Oncol 2007;25:4084-9
   PubMed Web of Science ®Google Scholar
• Weiss JF, Landauer MR. History and development of radiation-protective agents. Int J Radiat Biol 2009;85:539-73
   PubMed Web of Science ®Google Scholar
• Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007;12:738-47
   PubMed Web of Science ®Google Scholar
• Pellmar TC, Rockwell S, Radiological/Nuclear Threat Countermeasures Working Group. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 2005;163:115-23
   PubMedGoogle Scholar
• Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 2003;22:5734-54
   PubMed Web of Science ®Google Scholar
• Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 2003;189:1-20
   PubMed Web of Science ®Google Scholar
• Okunieff P, Swarts S, Keng P, Antioxidants reduce consequences of radiation exposure. Adv Exp Med Biol 2008;614:165-78
   PubMed Web of Science ®Google Scholar
• Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 2009;16:130-43
   PubMed Web of Science ®Google Scholar
• Medimmune Oncology I. Methods for the administration of amifostine and related compounds. US2006128672; 2006
   Google Scholar
• Praetorius NP, Mandal TK. Alternate delivery route for amifostine as a radio-/chemo-protecting agent. J Pharm Pharmacol 2008;60:809-15
   PubMed Web of Science ®Google Scholar
• Wisconsin Alumni Res Foundation. Amino thiol compounds and compositions for use in conjunction with cancer therapy. WO2005014524; 2005
   Google Scholar
• Eastern Virginia Medical school, Schellenberg KA. Methoxypolyethylene glycol thioester chelate and uses thereof. WO2007095178; 2007
   Google Scholar
• Jagetia GC. Radioprotection and radiosensitization by curcumin. Adv Exp Med Biol 2007;595:301-20
   PubMed Web of Science ®Google Scholar
• University of Rochester. Curcumin derivatives and their use as radioprotectors. WO2009023357; 2009
   Google Scholar
• Yoshida Y, Saito Y, Jones LS, Chemical reactivities and physical effects in comparison between tocopherols and tocotrienols: physiological significance and prospects as antioxidants. J Biosci Bioeng 2007;104:439-45
   PubMed Web of Science ®Google Scholar
• Sen CK, Khanna S, Roy S. Tocotrienols in health and disease: the other half of the natural vitamin E family. Mol Aspects Med 2007;28:692-728
   PubMed Web of Science ®Google Scholar
• Kumar KS, Srinivasan V, Toles R, Nutritional approaches to radioprotection: vitamin E. Mil Med 2002;167:57-9
   PubMedGoogle Scholar
• Henry M. Jackson Foundation for Advancement of Military Med. Method and composition of administering radioprotectants WO2005020935; 2005
   Google Scholar
• Henry M. Jackson Foundation for Advancement of Military Med. Radiation protection by gamma-tocotrienol. EP1593127; 2005
   Google Scholar
• Ghosh SP, Kulkarni S, Hieber K, Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol 2009;85:598-606
   PubMed Web of Science ®Google Scholar
• Singh VK, Shafran RL, Jackson WE, Induction of cytokines by radioprotective tocopherol analogs. Exp Mol Pathol 2006;81:55-61
   PubMed Web of Science ®Google Scholar
• Berbée M, Fu Q, Boerma M, Gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. Radiat Res 2009;171:596-605
   PubMed Web of Science ®Google Scholar
• Wang J, Boerma M, Fu Q, Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys 2007;68:1483-90
   PubMed Web of Science ®Google Scholar
• Henry M. Jackson Foundation for the Advancement of Military Med., Yasoo Health. Delta-tocotrienol as a radioprotective countermeasure agent. WO2009126866; 2009
   Google Scholar
• Martin RF, Broadhurst S, Reum ME, In vitro studies with methylproamine: a potent new radioprotector. Cancer Res 2004;64:1067-70
   PubMed Web of Science ®Google Scholar
• Peter MacCallum Cancer Institute. Radioprotector compounds and related methods. WO2008074091; 2008
   Google Scholar
• Epperly M, Jin S, Nie S, Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. Radiat Res 2007;168:552-9
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh. Radioprotective agents. WO2007014237; 2007
   Google Scholar
• Liang X, Chavez AR, Schapiro NE, Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 2009;86:599-607
   PubMed Web of Science ®Google Scholar
• Tarnuzzer RW, Colon J, Patil S, Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett 2005;5:2573-7
   PubMed Web of Science ®Google Scholar
• Edward Via Virginia College of Osteopathic Medicine. Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles. WO2007002662; 2007
   Google Scholar
• Colon J, Herrera L, Smith J, Protection from radiation-induced pneumonitis using cerium oxide nanoparticles. Nanomedicine 2009;5:225-31
   PubMed Web of Science ®Google Scholar
• Epperly MW, Gretton JE, Sikora CA, Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiat Res 2003;160:568-78
   PubMed Web of Science ®Google Scholar
• Zabbarova I, Kanai A. Targeted delivery of radioprotective agents to mitochondria. Mol Interv 2008;8:294-302
   PubMedGoogle Scholar
• Kagan VE, Wipf P, Stoyanovsky D, Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. Adv Drug Deliv Rev 2009; In press
   PubMed Web of Science ®Google Scholar
• Soule BP, Hyodo F, Matsumoto K, The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007;42:1632-50
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh. Selective targeting agents for mitochondria. US2007161573; 2007
   Google Scholar
• Jiang J, Kurnikov I, Belikova NA, Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther 2007;320:1050-60
   PubMed Web of Science ®Google Scholar
• Jiang J, Belikova NA, Hoye AT, A mitochondria-targeted nitroxide/hemigramicidin S conjugate protects mouse embryonic cells against gamma irradiation. Int J Radiat Oncol Biol Phys 2008;70:816-25
   PubMed Web of Science ®Google Scholar
• Epperly M, Pierce J, Dixon T, The mitochondrial targeted GS-nitroxide JP4-039 is radioprotective in vitro and in vivo. Int J Radiat Oncol Biol Phys 2008;72:S82
   Web of Science ®Google Scholar
• Greenberger JS, Epperly MW. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo 2007;21:141-6
   PubMed Web of Science ®Google Scholar
• Borrelli A, Schiattarella A, Mancini R, A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. Free Radic Biol Med 2009;46:110-16
   PubMed Web of Science ®Google Scholar
• Day BJ. Catalytic antioxidants: a radical approach to new therapeutics. Drug Discov Today 2004;9:557-66
   PubMed Web of Science ®Google Scholar
• Duke University, Batinic-Haberle I. Substituted porphyrins. WO2005077269; 2005
   Google Scholar
• Aeolus Sciences, Inc, Duke University. Cancer Therapy. US2007149498; 2007
   Google Scholar
• Rabbani ZN, Batinic-Haberle I, Anscher MS, Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int J Radiat Oncol Biol Phys 2007;67:573-80
   PubMed Web of Science ®Google Scholar
• Rabbani ZN, Salahuddin FK, Yarmolenko P, Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation. Free Radic Res 2007;41:1273-82
   PubMed Web of Science ®Google Scholar
• Rabbani Z, Jackson IL, Batinic-Haberle I, Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 improves survival and protects lungs from radiation. Radiation Research Society 55th Annual Meeting 2009; Abstract PS4.53
   Google Scholar
• Gridley DS, Makinde AY, Luo X, Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res 2007;27:3101-9
   PubMed Web of Science ®Google Scholar
• Pollard JM, Reboucas JS, Durazo A, Radio-protective effects of manganese-containing superoxide dismutase mimics on ataxia telangiectasia cells. Free Radic Biol Med 2009;47:250-60
   PubMed Web of Science ®Google Scholar
• Eukarion, Inc. Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases. EP1688425; 2006
   Google Scholar
• Srinivasan V, Doctrow S, Singh VK, Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol 2008;30:271-90
   PubMed Web of Science ®Google Scholar
• Haupt S, Berger M, Goldberg Z, Apoptosis - the p53 network. J Cell Sci 2003;116:4077-85
   PubMed Web of Science ®Google Scholar
• Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003;22:5897-906
   PubMed Web of Science ®Google Scholar
• Pietsch EC, Sykes SM, McMahon SB, The p53 family and programmed cell death. Oncogene 2008;27:6507-21
   PubMed Web of Science ®Google Scholar
• Gudkov AV, Komarova EA. Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 2007;16:R67-72
   PubMed Web of Science ®Google Scholar
• University of Illinois. P53 inhibitors and therapeutic use of the same. US2005222224; 2005
   Google Scholar
• Sohn D, Graupner V, Neise D, Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ 2009;16:869-78
   PubMed Web of Science ®Google Scholar
• Davidson W, Ren Q, Kari G, Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. Cell Cycle 2008;7:1224-30
   PubMed Web of Science ®Google Scholar
• Cottan HB, Carson DA, Barchechath S. Compounds having activity as inhibitors of apoptosis. US2006122178; 2006
   Google Scholar
• Strom E, Sathe S, Komarov PG, Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006;2:474-9
   PubMed Web of Science ®Google Scholar
• Komarova EA, Kondratov RV, Wang K, Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004;23:3265-71
   PubMed Web of Science ®Google Scholar
• Qiu W, Carson-Walter EB, Liu H, PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2008;2:576-83
   PubMed Web of Science ®Google Scholar
• Takai H, Naka K, Y O, Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002;21:5195-205
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV. 2-phenyl-benzimidazol and 2-phenyl-imidazo-4,5-pyridine derovatives as checkpoint kinase CDS1 (Chk2) inhibitors in the treatment of cancer. EP1613313; 2006
   Google Scholar
• Arienti KL, Brunmark A, Axe FU, Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 2005;48:1873-85
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals International. 3-hydroxyisothiazole- 4-carboxamide derivatives as Chk2 inhibitors. WO2008157802; 2008
   Google Scholar
• Carlessi L, Buscemi G, Larson G, Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007;6:935-44
   PubMed Web of Science ®Google Scholar
• Temple University. Protection of tissues and cells from cytotoxic effects of ionizing radiation by Abl inhibitors. WO2005065074; 2005
   Google Scholar
• Yoshida K, Miki Y. Enabling death by the Abl tyrosine kinase: mechanisms for nuclear shuttling of c-Abl in response to DNA damage. Cell Cycle 2005;4:777-9
   PubMed Web of Science ®Google Scholar
• Onconova Therapeutics, Inc. Formulation of radioprotective alpha, beta unsaturated aryl sulfones. WO2007016201; 2007
   Google Scholar
• Onconova Therapeutics, Inc. Formulations of radioprotective alpha, beta unsaturated aryl sulfones WO2008105808; 2008
   Google Scholar
• Ghosh SP, Perkins MW, Hieber K, Radiation protection by a new chemical entity, Ex-Rad™: Efficacy and mechanisms. Radiat Res 2009;171:173-9
   PubMed Web of Science ®Google Scholar
• Bartkowiak D, Hipp PR, Mendonca MS, A radioprotective effect of imatinib (Gleevec) in human squamous carcinoma cells. Strahlenther Onkol 2007;183:432-9
   PubMed Web of Science ®Google Scholar
• Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006;79:173-89
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. Use of GSK3 inhibitors in combination with radiation therapies. WO2006034207; 2006
   Google Scholar
• Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003;24:441-3
   PubMed Web of Science ®Google Scholar
• Thotala DK, Hallahan DE, Yazlovitskaya EM. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res 2008;68:5859-68
   PubMed Web of Science ®Google Scholar
• Thotala D, Hallahan D, Yazlovitskaya E. Radioprotection of small intestines and bone marrow by inhibition of glycogen synthase kinase-3 beta (GSK-3 beta). 50th ASTRO Meeting 2008; Abstract 3178
   Google Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Rev Mol Cell Biol 2008;9:139-50
   PubMed Web of Science ®Google Scholar
• Paris F, Fuks Z, Kang A, Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293:293-7
   PubMed Web of Science ®Google Scholar
• Sloan Kettering Institute for Cancer Research. Methods for treating and preventing GI syndrome and graft versus host disease. WO2008137901; 2008
   Google Scholar
• Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008;49:413-40
   PubMedGoogle Scholar
• University of Connecticut. Methods of inhibiting vascular permeability and apoptosis. WO2005002559; 2005
   Google Scholar
• Bonnaud S, Niaudet C, Pottier G, Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 2007;67:1803-11
   PubMed Web of Science ®Google Scholar
• Takabe K, Paugh SW, Milstien S, "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-95
   PubMed Web of Science ®Google Scholar
• Deng W, Balazs L, Wang DA, Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 2002;123:206-16
   PubMed Web of Science ®Google Scholar
• University of Tennessee Res Foundation. Radiation protection and treatment for exposure to gamma-radiation. WO2008140574; 2008
   Google Scholar
• Deng W, Shuyu E, Tsukahara R, The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 2007;132:1834-51
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:928-42
   PubMed Web of Science ®Google Scholar
• Li Y, Sun X, LaMont JT, Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 2003;100:2674-8
   PubMed Web of Science ®Google Scholar
• Suzuki M, Amano M, Choi J, Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 2006;165:525-31
   PubMed Web of Science ®Google Scholar
• Arqule, Inc. Methods of protecting against radiation injury. WO2005053682; 2005
   Google Scholar
• Karagiannis TC, El-Osta A. The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation. Cell Cycle 2006;5:288-95
   PubMed Web of Science ®Google Scholar
• Henry Ford Health Systems. Systems, methods and compositions for reduction of injury from radiation exposure. WO2009017948; 2009
   Google Scholar
• Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007;39:1367-74
   PubMed Web of Science ®Google Scholar
• US Secretary Department of Health and Human Services, Uniformed Services University of Health Sciences. Isoflavones against radiation-induced mortality. EP1767215; 2007
   Google Scholar
• Day RM, Barshishat-Kupper M, Mog SR, Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. J Radiat Res (Tokyo) 2008;49:361-72
   PubMed Web of Science ®Google Scholar
• Davis TA, Clarke TK, Mog SR, Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. Int J Radiat Biol 2007;83:141-51
   PubMed Web of Science ®Google Scholar
• Raffoul JJ, Wang Y, Kucuk O, Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006;6:107
   PubMed Web of Science ®Google Scholar
• Singh VK, Grace MB, Parekh VI, Effects of genistein administration on cytokine induction in whole-body gamma irradiated mice. Int Immunopharmacol 2009;9:1401-10
   PubMed Web of Science ®Google Scholar
• Zenk JL. New therapy for the prevention and prophylatic treatment of acute radiation syndrome. Expert Opin. Investig. Drugs 2007;16:767-70
   Web of Science ®Google Scholar
• Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med. 2008;44:1-13
   PubMed Web of Science ®Google Scholar
• Wang Y, Meng A, Lang H, Activation of nuclear factor kappaB in vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res 2004;64:6240-6
   PubMed Web of Science ®Google Scholar
• Cleveland Clinic Foundation, Gudkov AV. Methods of protecting against radiation using inducers of NF-kappaB. WO2005056055; 2005
   Google Scholar
• Carmody RJ, Chen YH. Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol 2007;4:31-41
   PubMed Web of Science ®Google Scholar
• Cleveland Clinic Foundation, Gudkov AV. Methods of protecting against radiation using flagellin. WO2005056042; 2005
   Google Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC, An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30
   PubMed Web of Science ®Google Scholar
• Cleveland Clinic Foundation. Flagellin related polypeptides and uses thereof. WO2006069198; 2006
   Google Scholar
• Krivokrysenko V, Toshkov I, Gleiberman A, Single injection of novel medical radiation countermeasure CBLB502 rescues non-human primates within broad time window after lethal irradiation. Radiation Research Society 55th Annual Meeting 2009; Abstract PS1.33
   Google Scholar
• Buwitt-Beckmann U, Heine H, Wiesmüller KH, Lipopeptide structure determines TLR2 dependent cell activation level. FEBS J 2005;272:6354-64
   PubMed Web of Science ®Google Scholar
• Cleveland Biolabs, Inc, Cleveland Clinic Foundation. Methods of protecting against apoptosis using lipopeptides. WO2006138238; 2006
   Google Scholar
• Srinivasan V, Condliffe D, Singh VK, Radiation countermeasure studies in mice with CBLB613, a TLR 2/6 agonist. Radiation Research Society 55th Annual Meeting 2009; Abstract PS4.44
   Google Scholar
• Bone F, Strom E, Young J, CBLB600s: a family of novel compounds with radioprotective and hematopoietic stem cells stimulating activity, acting via activation of TLR2 receptor complexes. 13th International Congress Radiation Research 2007; Abstract PS4139
   Google Scholar
• Neta R. Modulation of radiation damage by cytokines. Stem Cells 1997;15(Suppl 2):87-94
   PubMed Web of Science ®Google Scholar
• Singh VK, Yadav VS. Role of cytokines and growth factors in radioprotection. Exp Mol Pathol 2005;78:156-69
   PubMed Web of Science ®Google Scholar
• Hérodin F, Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp Hematol 2005;33:1071-80
   PubMed Web of Science ®Google Scholar
• Anderson FW, Zhao Y, Chen T. Uses of IL-12 in hematopoiesis. WO2005007093; 2005
   Google Scholar
• Chen T, Burke KA, Zhan Y, IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 2007;35:203-13
   PubMed Web of Science ®Google Scholar
• University of Southern California. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. US2009047241; 2009
   Google Scholar
• Basile LA, Gallaher TK, Shibata D, Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 2008;19:26-53
   Google Scholar
• Drouet M, Delaunay C, Grenier N, Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys. Haematologica 2008;93:465-6
   PubMed Web of Science ®Google Scholar
• Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage. WO2009094172; 2009
   Google Scholar
• Orschell CM, Plett A, Yamin M, ARA290 is an efficacious radiomitigator of both the hematopoietic and gastrointestinal syndromes of the acute radiation syndrome. Radiation Research Society 55th Annual Meeting 2009; Abstract PS6.45
   Google Scholar
• Satyamitra MM, Mullaney C, Ney P, A novel TPO agonist, Alxn4100TPO mitigates radiation induced lethality in CD2F1 mice by increasing thrombopoiesis. Radiation Research Society 55th Annual Meeting 2009; Abstract MS1102
   Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
   PubMed Web of Science ®Google Scholar
• Okunieff P, Mester M, Wang J, In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat Res 1998;150:204-11
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007;18:817-26
   PubMed Web of Science ®Google Scholar
• Curagen Corp. Prophylactic and therapeutic uses of FGF-20 in radiation protection. WO2006073417; 2006
   Google Scholar
• Ara G, Watkins BA, Zhong H, Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol 2008;84:401-12
   PubMed Web of Science ®Google Scholar
• Hagiwara A, Nakayama F, Motomura K, Comparison of expression profiles of several fibroblast growth factor receptors in the mouse jejunum: suggestive evidence for a differential radioprotective effect among major FGF family members and the potency of FGF1. Radiat Res 2009;172:58-65
   PubMed Web of Science ®Google Scholar
• Motomura K, Hagiwara A, Komi-Kuramochi A, An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection. Biochim Biophys Acta 2008;1780:1432-40
   PubMed Web of Science ®Google Scholar
• National Institute of Advanced Industrial Science and Technology. Medicinal composition containing highly functionalized chimeric protein. WO2009048119; 2009
   Google Scholar
• Yang S, Zhang M, Yin L, FGF-P mitigates bone marrow radiation damage. Radiation Research Meeting 2008; Abstract PS3518
   Google Scholar
• Xiao Z, Su Y, Yang S, Protective effect of esculentoside A on radiation-induced dermatitis and fibrosis. Int J Radiat Oncol Biol Phys 2006;65:882-9
   PubMed Web of Science ®Google Scholar
• University of Rochester. Methods and compositions related to esculentoside A. WO2006055875; 2006
   Google Scholar
• Cao Y, Yang S, Tian Y, Mitigation effect of esculentic acid on radiation-induced pneumonia and pulmonary fibrosis. Radiation Research Society 55th Annual Meeting 2009; Abstract PS1.41
   Google Scholar
• van den Berg HR, Khan NA, van der Zee M, Synthetic oligopeptides related to the [beta]-subunit of human chorionic gonadotropin attenuate inflammation and liver damage after (trauma) hemorrhagic shock and resuscitation. Shock 2009;31:285-91
   PubMed Web of Science ®Google Scholar
• Biotempt BV. Use of peptides for the control of radiation injury. WO2007102735; 2007
   Google Scholar
• Alfieri AA, Liu L, Bhanja P, Therapeutic protection of radiation-induced whole body damage by a small soluble peptide, EA230TM. Int J Radiat Oncol Biol Phys 2007;69:S125-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Qian J, Xing X, Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 2008;14:1868-76
   PubMed Web of Science ®Google Scholar
• Biogen Idec Inc. Pyrimidinylimidazoles as TGF-beta inhibitors. WO2006026306; 2006
   Google Scholar
• Anscher MS, Thrasher B, Zgonjanin L, Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008;71:829-37
   PubMed Web of Science ®Google Scholar
• Cassatt DR, Kaminski JM, Hatchett RJ, Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiat Res 2008;170:540-8
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng H, Ou X, Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis. Am J Pathol 2002;160:2063-72
   PubMed Web of Science ®Google Scholar
• Schering Corp, University of Kansas. Methods to treat and/or prevent radiation- and/or chemical induced toxicity in non-maligant tissue. WO2008016378; 2008
   Google Scholar
• Wang J, Zheng H, Hauer-Jensen M. Influence of short-term octreotide administration on chronic tissue injury, transforming growth factor beta (TGF-beta) overexpression, and collagen accumulation in irradiated rat intestine. J Pharmacol Exp Ther 2001;297:35-42
   PubMed Web of Science ®Google Scholar
• Novartis AG. Somatostatin analogues. US2009069225; 2009
   Google Scholar
• Fu Q, Berbee M, Boerma M, The somatostatin analog SOM230 (pasireotide) ameliorates injury of the intestinal mucosa and increases survival after total body irradiation by inhibiting exocrine pancreatic secretion. Radiat Res 2009;171:698-707
   PubMed Web of Science ®Google Scholar
• Stanford Research Institute International. Oral DTPA for radionuclide chelation. WO2007145682; 2007
   Google Scholar
• University of Florida. Desferrithiocin analogue actinide decorporation agents. WO2008130395; 2008
   Google Scholar
• Bergeron RJ, Wiegand J, Singh S. Desferrithiocin analogue uranium decorporation agents. Int J Radiat Biol 2009;85:348-61
   PubMed Web of Science ®Google Scholar
• Moroni M, V. CT, Moccia KD, Development of a radiation injury model based on Gottingen minipig (Sus scrofa domestica). Radiation Research Society 55th Annual Meeting 2009; Abstract PS4.35
   Google Scholar
• Mori E, Takahashi A, Yamakawa N, High LET heavy ion radiation induces p53-independent apoptosis. J Radiat Res (Tokyo) 2009;50:37-42
   PubMed Web of Science ®Google Scholar
• Lindsay KJ, Coates PJ, Lorimore SA, The genetic basis of tissue responses to ionizing radiation. Br J Radiol 2007;80:S2-6
   Web of Science ®Google Scholar
• Barnett GC, West CM, Dunning AM, Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134-42
   PubMed Web of Science ®Google Scholar